GlassScriptPhysician profile
Laken J Kuntz
NPI 1700426962
$14,363.28
in general payments reported to CMS, 2019-2025
28 companies · $6,329 in 2025
The $6,329 reported for 2025 was more than what 99% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
See the full distribution for Gerontology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $654 · 2022: $2,062 · 2023: $1,601 · 2024: $3,718 · 2025: $6,329.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,000 · Food and Beverage: $3,545 · Education: $103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,000.00 |
| Food and Beverage | $3,545.17 |
| Education | $102.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $10,208.59 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,012.71 | 2021-2024 | Entyvio |
| Regeneron Healthcare Solutions, INC. | $449.33 | 2022-2024 | Dupixent |
| Janssen Biotech, INC. | $359.15 | 2021-2025 | Stelara, Tremfya |
| Gilead Sciences, INC. | $331.91 | 2021-2023 | Epclusa |
| Ardelyx, INC. | $194.72 | 2022-2023 | Ibsrela |
| Celgene Corporation | $193.77 | 2021-2023 | Zeposia |
| Merck Sharp & Dohme LLC | $163.01 | 2024-2025 | Dificid, Zerbaxa, Prevymis |
| E.R. Squibb & Sons, L.L.C. | $160.50 | 2022 | |
| Ferring Pharmaceuticals INC. | $146.80 | 2021-2023 | Rebyota |
| Novo Nordisk INC | $146.79 | 2023-2024 | Wegovy |
| Redhill Biopharma INC. | $139.58 | 2021-2023 | Talicia |
| Genzyme Corporation | $129.57 | 2022-2024 | |
| Braintree Laboratories, INC. | $119.95 | 2021-2024 | Sutab, Suflave |
| Amgen INC. | $87.43 | 2022-2023 | Avsola, Amjevita |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $76.32 | 2023-2024 | Idacio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $71.08 | 2022-2024 | Xifaxan, Trulance |
| Phathom Pharmaceuticals, INC. | $60.85 | 2024 | Voquezna |
| Daiichi Sankyo INC. | $60.68 | 2021-2024 | Injectafer |
| Pfizer INC. | $57.09 | 2024 | |
| Digestive Care, INC. | $38.54 | 2023 | Pertzye |
| Aimmune Therapeutics, INC. | $34.06 | 2024-2025 | Zenpep |
| Nestle Healthcare Nutrition INC. | $33.52 | 2022-2023 | |
| Ironwood Pharmaceuticals, INC | $20.16 | 2023 | Linzess |
| Celltrion USA INC. | $18.91 | 2024 | Zymfentra |
| Boston Scientific Corporation | $16.55 | 2025 | Watchman Flx |
| Sandoz INC. | $16.34 | 2024 | Hyrimoz |
| Bayer Healthcare Pharmaceuticals INC. | $15.37 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laken Kuntz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.